Welcome to our dedicated page for Barclays SEC filings (Ticker: BCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Barclays PLC’s disclosures are as multifaceted as its universal banking model—spanning retail mortgages in the UK to global investment-bank trading desks. When credit risk, capital ratios, and trading income all sit in separate sections, parsing the story hidden inside a 300-page filing can be daunting. Investors hunting for stress-test results, dividend capacity, or the latest Barclays insider trading Form 4 transactions need a faster route. Our platform offers Barclays SEC filings explained simply for any skill level.
This page gathers every Barclays submission to the SEC and pairs it with Stock Titan’s AI. The technology delivers sentence-level highlights, plain-English glossaries, and trend charts so you can move from raw document to insight in minutes. Use the Barclays quarterly earnings report 10-Q filing to follow trading revenue and net interest margin, consult the Barclays annual report 10-K simplified for Basel III capital disclosures, or skim our AI digest of each Barclays 8-K material events explained to monitor market-moving announcements. Need ownership signals? Real-time alerts on Barclays Form 4 insider transactions real-time flag every executive share sale or purchase.
Professionals rely on these tools to:
- Compare quarter-over-quarter performance with our Barclays earnings report filing analysis
- Track Barclays executive stock transactions Form 4 before earnings releases
- Review the Barclays proxy statement executive compensation to benchmark pay against peers
All documents arrive within seconds of hitting EDGAR, and each comes with an on-page “understanding Barclays SEC documents with AI” summary that clarifies accounting jargon, highlights segment drivers, and links directly to tables of interest. No more Ctrl-F hunts—just actionable context delivered the moment it matters.
Form 4 filing for AnaptysBio, Inc. (ANAB) dated 07/03/2025 discloses that director Hollings Renton executed expiring stock options and immediately sold most of the resulting shares under a pre-arranged Rule 10b5-1 trading plan.
- Option exercise: 20,925 options were exercised at an exercise price of $6.93 (grant dated 07/06/2015, expiring 07/05/2025).
- Share sales: • 7,250 shares sold at a weighted-average $23.0908 • 13,675 shares sold at a weighted-average $23.8232. The weighted-average sale ranges were $22.425–$23.395 and $23.56–$24.015, respectively.
- Post-transaction holdings: Direct common-stock ownership declined from 25,890 to 4,965 shares. The insider retains ≥112,051 additional option shares that vest per their original schedules.
- The trades were executed pursuant to a Rule 10b5-1 plan adopted on 03/14/2024, signalling pre-planned, non-discretionary activity ahead of the 07/05/2025 option expiration.
The filing represents routine expiration-driven option exercise coupled with partial monetisation. While the insider’s direct share count fell by roughly 81%, his large remaining option position maintains exposure to future upside. No company operational or financial metrics are included; the disclosure is limited to insider ownership changes.
Barclays PLC (BCS) filed a Form 6-K containing 25 separate Regulatory News Service (RNS) exhibits covering: (i) daily progress on the 2025 share-buy-back programme announced on 14 February 2025, (ii) monthly total-voting-rights disclosure, and (iii) multiple notifications of dealings by persons discharging managerial responsibility (PDMRs).
Share-buy-back highlights
- Between 30 May 2025 and 25 June 2025 the bank repurchased 47.4 million ordinary shares for cancellation at prices between 317.05p and 334.10p, reducing the issued capital from 14,229,471,353 to 14,182,099,898 shares (-0.33%).
- Since programme launch (14 Feb 2025) Barclays has bought back 266,188,377 shares, equivalent to c.1.9 % of the starting share count, at a volume-weighted average price of 301.39p, spending roughly £0.80 bn.
- No shares are held in treasury; all repurchased stock has been cancelled, improving per-share metrics.
Total voting rights as at 31 May 2025 stand at 14,229,471,353; subsequent cancellations (above) will flow into the June month-end denominator.
PDMR transactions
- Routine quarterly fixed-remuneration share deliveries to 14 senior executives (price £3.256) plus immediate sales to cover tax.
- CEO C.S. Venkatakrishnan and CFO Anna Cross each received new Long-Term Incentive Plan (LTIP) conditional awards over 3.12 m and 1.70 m shares respectively (strike price reference £2.799; vesting 5 tranches over 7 years).
- A clerical correction was issued for Taylor Wright’s earlier disclosure; the underlying data were unchanged.
No earnings, guidance or financing updates are included; the filing is strictly administrative, evidencing capital-return execution and governance transparency.
FAQ
What is the current stock price of Barclays (BCS)?
What is the market cap of Barclays (BCS)?
What core services does Barclays offer?
How is Barclays organized?
Which industries does Barclays serve?
What differentiates Barclays from its competitors?
What is the focus of Barclays’ UK segment?
How does Barclays operate internationally?
What role does technology play in Barclays' strategy?
How does Barclays balance risk across its service areas?
